Lucia R. Languino, PhD
Professor, Department of Pharmacology, Physiology, & Cancer Biology
Director, Genetics, Genomics & Cancer Biology PhD Program
Contact Information
Professor, Department of Pharmacology, Physiology, & Cancer Biology
Director, Genetics, Genomics & Cancer Biology PhD Program
Research & Clinical Interests
Studies of the signaling pathways that contribute to prostate cancer progression and metastasis.
Dr. Languino investigates the role of cell adhesion receptors in phenotypic changes of prostate cancer cells. A strong research focus is being devoted to the study of the cross-talk between cell adhesion molecules, extracellular matrix proteins and growth factor receptors in vitro and in vivo systems and how this cross-talk affects intracellular signal transduction, cell survival, cell migration and cell division. Dr. Languino's research interests also focus on the cellular and molecular characterization of the metastatic process of prostate cancer with particular emphasis on the signals directing distant localization of prostate cancer cells
Selected Publications
- Expression of the αVβ3 integrin affects prostate cancer sEV cargo and density and promotes sEV pro-tumorigenic activity in vivo through a GPI-anchored receptor, NgR2
- Neuroendocrine gene subsets are uniquely dysregulated in prostate adenocarcinoma
- The αVβ6 integrin in cancer cell-derived small extracellular vesicles enhances angiogenesis
- Targeting the αVβ3/NgR2 pathway in neuroendocrine prostate cancer.
- The αvβ6 Integrin is Transferred Intercellularly via Exosomes
Recent Peer-Reviewed Publications
- Role of Kindlin 2 in prostate cancer
- Expression of the αVβ3 integrin affects prostate cancer sEV cargo and density and promotes sEV pro-tumorigenic activity in vivo through a GPI-anchored receptor, NgR2
- Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches
- Neuroendocrine gene subsets are uniquely dysregulated in prostate adenocarcinoma
- Targeting the αVβ3/NgR2 pathway in neuroendocrine prostate cancer